Monopar Therapeutics Q2 2025 10-Q Filed

Ticker: MNPR · Form: 10-Q · Filed: 2025-08-12T00:00:00.000Z

Sentiment: neutral

Topics: 10-Q, financials, pharmaceuticals

TL;DR

Monopar Therapeutics Q2 2025 10-Q: $6.1M cash on hand.

AI Summary

Monopar Therapeutics filed its 10-Q for the period ending June 30, 2025. The company reported cash and cash equivalents of $6,127,457 as of June 30, 2025. This filing details their financial position and business operations for the second quarter of 2025.

Why It Matters

This filing provides investors with an update on Monopar Therapeutics' financial health and operational status for the second quarter of 2025, including their cash reserves.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Monopar Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

$6,127,457 — Cash Equivalents (As of June 30, 2025, indicating the company's liquidity.)
40,000,000 — Authorized Shares (Indicates the total number of shares the company is authorized to issue.)

Key Players & Entities

Monopar Therapeutics (company) — Filer of the 10-Q
June 30, 2025 (date) — End of the reporting period
$6,127,457 (dollar_amount) — Cash equivalents as of June 30, 2025
20250812 (date) — Filing date

FAQ

What was Monopar Therapeutics' cash and cash equivalents balance as of June 30, 2025?

As of June 30, 2025, Monopar Therapeutics reported cash equivalents of $6,127,457.

What is the fiscal year end for Monopar Therapeutics?

Monopar Therapeutics' fiscal year ends on December 31.

What is the SIC code for Monopar Therapeutics?

The Standard Industrial Classification (SIC) code for Monopar Therapeutics is 2834, Pharmaceutical Preparations.

When was this 10-Q filing submitted to the SEC?

This 10-Q filing was submitted on August 12, 2025.

What does the term 'Forfeited options' refer to in the filing?

Forfeited options represent unvested shares and vested, unexercised and expired shares related to employee terminations.

From the Filing

0001437749-25-026042.txt : 20250812 0001437749-25-026042.hdr.sgml : 20250812 20250812080056 ACCESSION NUMBER: 0001437749-25-026042 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 59 CONFORMED PERIOD OF REPORT: 20250630 FILED AS OF DATE: 20250812 DATE AS OF CHANGE: 20250812 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39070 FILM NUMBER: 251204104 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 10-Q 1 mnpr20250630_10q.htm FORM 10-Q mnpr20250630_10q.htm 0001645469 Monopar Therapeutics Inc. false --12-31 Q2 2025 0.001 0.001 40,000,000 40,000,000 6,127,457 6,127,457 6,102,560 6,102,560 81,932 0 no 754,939 490,549 6,127,457 0.00 25.00 25.01 50.00 50.01 75.00 75.01 100.00 0 1.67 false false false false Cash equivalents as of March 31, 2025, and December 31, 2024, represent the fair value of the Company’s investments in money market accounts and U.S. Treasury securities with maturities at the date of purchase of three months or less. Cash equivalents as of December 31, 2024 and 2023, represent the fair value of the Company’s investment in money market accounts and U.S. Treasury securities with maturities at the date of purchase of three months or less. Cash equivalents as of June 30, 2025, and December 31, 2024, represent the fair value of the Company’s investments in money market accounts and U.S. Treasury securities with maturities at the date of purchase of three months or less. Forfeited options represent unvested shares and vested, unexercised and expired shares related to employee terminations.? Information pertaining to number of shares outstanding and per share data gives retroactive effect to a 1 for 5 reverse stock split that became effective on August 12, 2024. Forfeitures only include known forfeitures to date as the Company accounts for forfeitures as they occur due to a limited history of forfeitures. 225,881 options vest as follows: options to purchase 8,270 shares of the Company’s common stock vesting immediately upon grant date; options to purchase 2,000 shares of the Company’s common stock vesting monthly over one year; options to purchase 51,143 shares of the Company’s common stock vesting quarterly over one year; options to purchase 164,468 shares of the Company’s common stock vesting 6/48ths on the six-month anniversary of vesting commencement date and 1/48th per month thereafter. 0001645469 2025-01-01 2025-06-30 xbrli:shares 0001645469 2025-07-31 thunderdome:item iso4217:USD 0001645469 2025-06-30 0001645469 2024-12-31 iso4217:USD xbrli:shares 0001645469 2025-04-01 2025-06-30 0001645469 2024-04-01 2024-06-30 0001645469 2024-01-01 2024-06-30 0001645469 us-gaap:CommonStockMember 2024-12-31 0001645469 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001645469 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001645469 us-gaap:RetainedEarningsMember 2024-12-31 0001645469 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001645469 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001645469 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001645469 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001645469 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2025-01-01 2025-03-31 0001645469 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001645469 us-gaap:AdditionalPaidInCapitalMem